Cingulate Therapeutics
Naama Courtemanche has a strong background in program management, quality assurance, and operations within the biotechnology and life sciences industry. Naama's expertise in regulatory CMC strategy, product development, manufacturing, and project management has been showcased in various roles at companies such as Cingulate Therapeutics, Genzyme, and Dexcom. Naama's academic background includes a Master of Business Administration from the University of Michigan and a Bachelor's Degree in Biology from Tel Aviv University.
This person is not in any offices
Cingulate Therapeutics
1 followers
Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products.